Comparing Intelligent Bio Solutions (INBS) & The Competition

Intelligent Bio Solutions (NASDAQ:INBS) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its peers? We will compare Intelligent Bio Solutions to similar companies based on the strength of its dividends, analyst recommendations, institutional ownership, earnings, valuation, profitability and risk.

Valuation and Earnings

This table compares Intelligent Bio Solutions and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Intelligent Bio Solutions	$4.22 million	-$12.43 million	-0.25
Intelligent Bio Solutions Competitors	$1.89 billion	$135.83 million	12.61

Intelligent Bio Solutions’ peers have higher revenue and earnings than Intelligent Bio Solutions. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Intelligent Bio Solutions and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Intelligent Bio Solutions	-294.88%	-175.35%	-91.25%
Intelligent Bio Solutions Competitors	-304.51%	-178.77%	-22.17%

Analyst Ratings

This is a summary of current recommendations and price targets for Intelligent Bio Solutions and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intelligent Bio Solutions	1	1	0	0	1.50
Intelligent Bio Solutions Competitors	4281	10558	18338	829	2.46

As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 18.88%. Given Intelligent Bio Solutions’ peers stronger consensus rating and higher possible upside, analysts clearly believe Intelligent Bio Solutions has less favorable growth aspects than its peers.

Institutional & Insider Ownership

33.0% of Intelligent Bio Solutions shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 1.3% of Intelligent Bio Solutions shares are held by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Intelligent Bio Solutions has a beta of 4.48, indicating that its stock price is 348% more volatile than the S&P 500. Comparatively, Intelligent Bio Solutions’ peers have a beta of 2.57, indicating that their average stock price is 157% more volatile than the S&P 500.

Summary

Intelligent Bio Solutions peers beat Intelligent Bio Solutions on 10 of the 13 factors compared.

Intelligent Bio Solutions Company Profile

Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.